NCT06664528 Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
| NCT ID | NCT06664528 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Cardiac Toxicity |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-02-28 |
| Primary Completion | 2028-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-02-28 with a primary completion date of 2028-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies. The main purposes of the study are the following: * Identify the demographic factors related to the onset of cardiotoxicity produced by anticancer drugs. * Identify any subgroups more likely to develop distant major adverse cardiovascular events (MACE). * Evaluate the usefulness of clinical, biohumoral and echocardiographic parameters for early diagnosis of cardiotoxicity. Participants will be monitored during the anticancer treatment via clinical, laboratory and instrumental evaluation according to the recommendation of the current guidelines on Cardio-Oncology (European Society of Cardiology, 2022). Initial follow-up will be 2 years.
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 18 at the time of evaluation * Patients treated with potentially cardiotoxic anticancer drugs * Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit. Exclusion Criteria: * Patients under the age of 18 at the time of evaluation * Patients whose documentation of the first visit is not available * Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone * Patient with poor acoustic window for echocardiographic examination. * Refusal of informed consent to participate in the study.
Contact & Investigator
Antonella Lombardo
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06664528 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Toxicity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06664528 currently recruiting?
Yes, NCT06664528 is actively recruiting participants. Contact the research team at antonella.lombardo@policlinicogemelli.it for enrollment information.
Where is the NCT06664528 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06664528 clinical trial?
NCT06664528 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Antonella Lombardo at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 300 participants.